1103 Combinatory analysis of CfDNA and CtDNA as a predictive and follow up tool to improve endometrial cancer management

Introduction/Background Minimally invasive biomarkers allow for the dynamic characterization of the disease. In the past years, there has been a rise on advanced endometrial cancers (EC) patients resulting in an increase on the mortality rates. This clinical paradigm highlights the need to find prognostic biomarkers that helps to identify those patients with worse clinical prognosis. Methodology Plasma samples and the uterine aspirate (UA) from 148 patients with EC were collected in different hospitals within Spain at baseline and throughout the course of the disease (n=120). Total cfDNA was isolated from all plasma samples and analysed for the presence of ctDNA based on the mutational profile found on the UA. Results High levels of cfDNA and detectable levels of ctDNA at baseline correlate with poor prognosis, in both PFS (Log-rank test p-valueConclusion High levels of cfDNA and detectable levels of ctDNA at baseline correlate with poor prognosis. Additionally, the longitudinal ctDNA monitoring allowed for the early identification of recurrences. Implementation of cfDNA/ctDNA analyses into the clinic could improve the management of the EC patients. Disclosures The authors declare no conflict of interests.